VCRE — Vicore Pharma Holding AB
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2124403 ·
Sweden
Last close
$13.78
Market Cap
—
52W High
$17.80
52W Low
$13.09
ADV30
167,220
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 602,000 | 602,000 | -123,845,000 | -108,616,000 | 1,077,265,000 | 377,423,000 | 86,354,000 |
| Dec 2025 | 419,000 | 419,000 | -133,707,000 | -137,103,000 | 1,218,637,000 | 578,147,000 | 123,175,000 |
| Sep 2025 | — | — | — | — | — | — | — |
| Jun 2025 | 1,746,000 | 1,746,000 | -111,171,000 | -115,363,000 | 976,501,000 | 351,604,000 | 68,250,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-391,683,000
Investing CF
$-910,158,000
Financing CF
$430,544,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-07-03
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,920,916,000
Inventory
—
Receivables
—
ST Investments
$682,371,000
EBIT TTM
$-422,436,000
Pretax Income TTM
$-472,531,000
Interest Exp TTM
$50,095,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,817,000 | -454,445,000 | -477,474,000 | 1,218,637,000 | 123,175,000 | — | -375,737,000 |
| Dec 2024 | 109,346,000 | -190,360,000 | -168,634,000 | 1,195,574,000 | 66,245,000 | — | -164,946,000 |
| Dec 2023 | 0 | -320,889,000 | -310,942,000 | 497,838,000 | 42,449,000 | — | -249,583,000 |
| Dec 2022 | 0 | -287,494,000 | -288,422,000 | 338,007,000 | 48,924,000 | — | -299,919,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1188.58 | — |
| JNJ | JOHNSON & JOHNSON | $618.61B | $256.98 | — |
| ABBV | AbbVie Inc. | $438.31B | $248.08 | — |
| MRK | Merck & Co., Inc. | $305.12B | $123.54 | — |
| NVS | NOVARTIS AG | $293.94B | $154.05 | — |
News headlines (Yahoo Finance, 1h cache)
Vicore Pharma to Participate in the Leerink Therapeutics Forum
2026-07-07 06:20 · Yahoo
Citi Appointed as Depositary Bank for Vicore Pharma Holding AB’s ADR Program
2026-07-06 07:00 · Yahoo
Vicore Pharma Appoints Rob Slack as Chief Scientific Officer
2026-07-06 06:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.